Pharmaceutical

White House ‘naloxone summit’ omitting prominent advoca...

To combat the opioid crisis, the White House is convening naloxone makers, but l...

STAT+: USDA to push food producers to substantiate clai...

Claims that livestock are raised without antibiotics "must be backed by empirica...

Suicides and homicides among young Americans jumped ear...

In 2021, there were about 2,900 suicides in youths ages 10 to 19, and 4,200 in 2...

STAT+: Pharmalittle: PBMs are targeted in yet another c...

Expanded access to a new Alzheimer’s drug is unlikely to happen quickly even if ...

STAT+: Instead of credible data, PDS Biotech delivers ‘...

PDS Biotech's disclosures have been opaque and confusing — and maybe on purpose,...

Black former NFL players more burdened by chronic pain ...

Julius Thomas: “It's important for people to understand that there's not a statu...

Mandy Cohen, seen as next CDC director, would bring pol...

The CDC may be about to undergo a paradigm shift with the anticipated appointmen...

Opinion: STAT+: How I’m helping companies think through...

Employers and employees could fall into opposing camps, with workers demanding t...

Opinion: What happens when patients beat their doctors ...

Have you ever received test results in your email and found yourself panic-Googl...

Confo Therapeutics and AbCellera partner on GPCR-target...

Confo Therapeutics’s technology stabilises the selected GPCRs in their disease-r...

Streamlining healthcare with AI for drug development

Healthcare R&D teams are increasingly using AI for drug development. Learn more ...

How using AI in clinical trials accelerates drug develo...

The use of AI in clinical trials is improving pharmaceutical R&D, speeding up ti...

The potential of AI in pharma R&D

Developing a new drug is a monumental achievement — the reward of years of resea...

FDA accepts Ipsen’s sNDA for mPDAC therapy

The sNDA was submitted based on data obtained from the Phase III NAPOLI 3 trial.

FDA approves Amneal’s 505(b)(2) NDA for PEMRYDI RTU

PEMRYDI RTU is the first and only ready-to-use presentation of pemetrexed for in...

Sandoz targets barriers to biosimilar accessibility wit...

The company hopes to work with stakeholders to improve access to biosimilars acr...